BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16876289)

  • 1. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population.
    Park SH; Choi JE; Kim EJ; Jang JS; Han HS; Lee WK; Kang YM; Park JY
    Lung Cancer; 2006 Oct; 54(1):19-24. PubMed ID: 16876289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
    Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
    Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
    Asomaning K; Reid AE; Zhou W; Heist RS; Zhai R; Su L; Kwak EL; Blaszkowsky L; Zhu AX; Ryan DP; Christiani DC; Liu G
    Clin Cancer Res; 2008 Jun; 14(12):4010-5. PubMed ID: 18559624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
    Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
    Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.
    Piotrowski P; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
    Int J Biol Markers; 2012 Jul; 27(2):e105-10. PubMed ID: 22467100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Mouse Double Minute 2 -309T>G Polymorphism with Acute Myeloid Leukemia in an Iranian Population: A Case- Control Study.
    Soleymannejad M; Sheikhha MH; Neamatzadeh H
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3037-3041. PubMed ID: 31653152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
    Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
    Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
    Heist RS; Zhou W; Chirieac LR; Cogan-Drew T; Liu G; Su L; Neuberg D; Lynch TJ; Wain JC; Christiani DC
    J Clin Oncol; 2007 Jun; 25(16):2243-7. PubMed ID: 17538168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis.
    Li G; Zhai X; Zhang Z; Chamberlain RM; Spitz MR; Wei Q
    Carcinogenesis; 2006 Oct; 27(10):2028-33. PubMed ID: 16675470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer.
    Jang JS; Lee SJ; Choi JE; Cha SI; Lee EB; Park TI; Kim CH; Lee WK; Kam S; Choi JY; Kang YM; Park RW; Kim IS; Cho YL; Jung TH; Han SB; Park JY
    Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2474-80. PubMed ID: 16284366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
    Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
    Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
    Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
    Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.
    Liu G; Wheatley-Price P; Zhou W; Park S; Heist RS; Asomaning K; Wain JC; Lynch TJ; Su L; Christiani DC
    Int J Cancer; 2008 Feb; 122(4):915-8. PubMed ID: 17957785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
    Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
    Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
    Maruei-Milan R; Heidari Z; Salimi S
    J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O6-alkylguanine-DNA alkyltransferase gene polymorphisms and the risk of primary lung cancer.
    Chae MH; Jang JS; Kang HG; Park JH; Park JM; Lee WK; Kam S; Lee EB; Son JW; Park JY
    Mol Carcinog; 2006 Apr; 45(4):239-49. PubMed ID: 16385589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
    Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer.
    Jun HJ; Park SH; Lee WK; Choi JE; Jang JS; Kim EJ; Cha SI; Kim DS; Kam S; Kim CH; Kang YM; Jung TH; Park JY
    Mol Carcinog; 2007 Feb; 46(2):100-5. PubMed ID: 17013834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.